CL2024000565A1 - Anticuerpos anti-psma y usos de los mismos. - Google Patents
Anticuerpos anti-psma y usos de los mismos.Info
- Publication number
- CL2024000565A1 CL2024000565A1 CL2024000565A CL2024000565A CL2024000565A1 CL 2024000565 A1 CL2024000565 A1 CL 2024000565A1 CL 2024000565 A CL2024000565 A CL 2024000565A CL 2024000565 A CL2024000565 A CL 2024000565A CL 2024000565 A1 CL2024000565 A1 CL 2024000565A1
- Authority
- CL
- Chile
- Prior art keywords
- psma antibodies
- psma
- antibodies
- antigen
- radioconjugates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1072—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
- A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Reproductive Health (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163237663P | 2021-08-27 | 2021-08-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2024000565A1 true CL2024000565A1 (es) | 2024-08-30 |
Family
ID=85322846
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2024000565A CL2024000565A1 (es) | 2021-08-27 | 2024-02-23 | Anticuerpos anti-psma y usos de los mismos. |
Country Status (15)
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10806806B2 (en) | 2016-06-23 | 2020-10-20 | Cornell University | Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies |
| SG11201811482YA (en) | 2016-06-23 | 2019-01-30 | Univ Cornell | Double targeted constructs to affect tumor kill |
| KR102724812B1 (ko) | 2017-04-05 | 2024-11-01 | 코넬 유니버시티 | 영상화 및 항종양 치료요법에 유용한 조정 가능한 약동학을 갖는 삼작용성 작제물 |
| KR20210116437A (ko) | 2018-11-20 | 2021-09-27 | 코넬 유니버시티 | 방사성핵종의 마크로사이클릭 복합체 및 암의 방사선 요법에서의 이의 용도 |
| US20230346862A1 (en) | 2022-05-02 | 2023-11-02 | Athanor Biosciences, Inc. | Cancer eradicating - bio-nanoparticles (ce-bnp) |
| WO2023215560A1 (en) | 2022-05-05 | 2023-11-09 | Atoosa Corporation | Tumor cell/immune cell multivalent receptor engager – bio-nanoparticle (timre-bnp) |
| TW202442689A (zh) | 2023-03-03 | 2024-11-01 | 美商亞森諾生物科學公司 | 靶向psma及ca9之系統 |
| WO2025183244A1 (ko) * | 2024-02-29 | 2025-09-04 | 주식회사 피비앱셀 | Psma에 대한 항체 및 그의 용도 |
| WO2026162289A1 (en) * | 2025-01-29 | 2026-08-06 | Philogen S.P.A. | High-affinity cross-reactive anti-psma antibodies |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US541606A (en) | 1895-06-25 | Sealed package | ||
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5606040A (en) | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
| US5770701A (en) | 1987-10-30 | 1998-06-23 | American Cyanamid Company | Process for preparing targeted forms of methyltrithio antitumor agents |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
| US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
| US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
| US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
| US6818749B1 (en) | 1998-10-31 | 2004-11-16 | The United States Of America As Represented By The Department Of Health And Human Services | Variants of humanized anti carcinoma monoclonal antibody cc49 |
| AU767394C (en) | 1999-12-29 | 2005-04-21 | Immunogen, Inc. | Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| DE60131456T2 (de) | 2000-11-30 | 2008-07-10 | Medarex, Inc., Milpitas | Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern |
| AU2002368077B2 (en) | 2001-07-12 | 2010-03-04 | Jefferson Foote | Super humanized antibodies |
| WO2003034903A2 (en) * | 2001-10-23 | 2003-05-01 | Psma Development Company, L.L.C. | Psma antibodies and protein multimers |
| EP1391213A1 (en) | 2002-08-21 | 2004-02-25 | Boehringer Ingelheim International GmbH | Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents |
| US8748356B2 (en) | 2007-10-19 | 2014-06-10 | Janssen Biotech, Inc. | Methods for use in human-adapting monoclonal antibodies |
| AU2008343589A1 (en) | 2007-12-19 | 2009-07-09 | Centocor Ortho Biotech Inc. | Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods |
| JP2012505654A (ja) | 2008-10-14 | 2012-03-08 | ヤンセン バイオテツク,インコーポレーテツド | 抗体をヒト化及び親和性成熟する方法 |
| US9221902B2 (en) | 2008-11-07 | 2015-12-29 | Fabrus, Inc. | Combinatorial antibody libraries and uses thereof |
| PL3248462T3 (pl) | 2010-03-31 | 2024-07-08 | Ablexis, Llc | Modyfikacja myszy metodami inżynierii genetycznej w celu wytworzenia przeciwciał chimerycznych |
| CN103221398B (zh) | 2010-07-23 | 2016-03-23 | 特拉华大学 | 用于快速构建放射性核素标记探针的四嗪-反式环辛烯连接反应 |
| BR112013027224A8 (pt) * | 2011-04-22 | 2018-08-14 | Emergent Product Dev Seattle | Proteínas de ligação de antígeno de membrana específico de próstata e composições e métodos relacionados |
| CA2880791A1 (en) | 2011-08-03 | 2013-02-07 | Children's Medical Center Corporation | A broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza hemagglutinin |
| US10556024B2 (en) | 2013-11-13 | 2020-02-11 | Whitehead Institute For Biomedical Research | 18F labeling of proteins using sortases |
| GB201506393D0 (en) * | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| JP7366518B2 (ja) | 2015-05-06 | 2023-10-23 | ヤンセン バイオテツク,インコーポレーテツド | 前立腺特異的膜抗原結合フィブロネクチンiii型ドメイン |
| CR20180243A (es) | 2015-10-02 | 2018-07-31 | Genentech Inc | Conjugados de anticuerpo-fármaco de pirrolobenzodiazepina y métodos de uso |
| EP3365369A1 (en) * | 2015-10-23 | 2018-08-29 | Pfizer Inc | Anti-il-2 antibodies and compositions and uses thereof |
| PT3370768T (pt) * | 2015-11-03 | 2022-04-21 | Janssen Biotech Inc | Anticorpos que se ligam especificamente ao pd-1 e seus usos |
| JP2019506155A (ja) * | 2016-01-12 | 2019-03-07 | クレッシェンド、バイオロジックス、リミテッドCrescendo Biologics Limited | 治療分子 |
| SG11201810470XA (en) * | 2016-06-10 | 2018-12-28 | Eisai R&D Man Co Ltd | Lysine conjugated immunoglobulins |
| ES2992988T3 (en) | 2017-03-30 | 2024-12-20 | Univ Cornell | Macrocyclic complexes of alpha-emitting radionuclides and their use in targeted radiotherapy of cancer |
| BR112020023508A2 (pt) * | 2018-05-24 | 2021-03-30 | Janssen Biotech, Inc. | Anticorpos anti-cd3 e usos dos mesmos |
| WO2020001344A1 (en) * | 2018-06-29 | 2020-01-02 | Beijing Biocytogen Co., Ltd | ANTI-CD3e ANTIBODIES AND USES THEREOF |
| EP3830132B1 (en) * | 2018-07-31 | 2022-11-23 | Heidelberg Pharma Research GmbH | Humanized antibodies against psma |
| CN109467602A (zh) * | 2018-11-05 | 2019-03-15 | 暨南大学 | 与cxcr4结合的人源蛋白及其应用 |
| KR20210116437A (ko) | 2018-11-20 | 2021-09-27 | 코넬 유니버시티 | 방사성핵종의 마크로사이클릭 복합체 및 암의 방사선 요법에서의 이의 용도 |
| CA3136892A1 (en) * | 2019-04-19 | 2020-10-22 | Janssen Biotech, Inc. | Methods of treating renal cancer with an anti- psma/cd3 antibody |
| ES3075769T3 (en) | 2019-05-10 | 2026-08-07 | Janssen Biotech Inc | Macrocyclic chelators and methods of use thereof |
-
2022
- 2022-08-25 WO PCT/IB2022/057978 patent/WO2023026235A1/en not_active Ceased
- 2022-08-25 MX MX2024002476A patent/MX2024002476A/es unknown
- 2022-08-25 CN CN202280072247.7A patent/CN118176213B/zh active Active
- 2022-08-25 KR KR1020247009640A patent/KR20240049342A/ko active Pending
- 2022-08-25 AU AU2022333321A patent/AU2022333321A1/en not_active Abandoned
- 2022-08-25 IL IL311070A patent/IL311070A/en unknown
- 2022-08-25 EP EP22860756.0A patent/EP4392454A4/en active Pending
- 2022-08-25 JP JP2024512988A patent/JP2024535712A/ja active Pending
- 2022-08-25 CA CA3230346A patent/CA3230346A1/en active Pending
- 2022-08-25 PE PE2024000311A patent/PE20240727A1/es unknown
- 2022-08-25 US US17/895,295 patent/US11987641B2/en active Active
-
2024
- 2024-02-23 CL CL2024000565A patent/CL2024000565A1/es unknown
- 2024-02-26 JO JOJO/P/2024/0041A patent/JOP20240041A1/ar unknown
- 2024-02-26 DO DO2024000036A patent/DOP2024000036A/es unknown
- 2024-02-26 CO CONC2024/0002244A patent/CO2024002244A2/es unknown
- 2024-04-10 US US18/631,269 patent/US20240270870A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2024002476A (es) | 2024-05-20 |
| CA3230346A1 (en) | 2023-03-02 |
| IL311070A (en) | 2024-04-01 |
| CN118176213A (zh) | 2024-06-11 |
| CO2024002244A2 (es) | 2024-03-07 |
| CN118176213B (zh) | 2025-09-23 |
| US20230131727A1 (en) | 2023-04-27 |
| US11987641B2 (en) | 2024-05-21 |
| WO2023026235A1 (en) | 2023-03-02 |
| AU2022333321A1 (en) | 2024-04-11 |
| DOP2024000036A (es) | 2024-07-31 |
| PE20240727A1 (es) | 2024-04-15 |
| KR20240049342A (ko) | 2024-04-16 |
| JOP20240041A1 (ar) | 2024-02-26 |
| EP4392454A1 (en) | 2024-07-03 |
| EP4392454A4 (en) | 2025-10-15 |
| JP2024535712A (ja) | 2024-10-02 |
| US20240270870A1 (en) | 2024-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2024002244A2 (es) | Anticuerpos anti-psma y usos de estos | |
| UY39912A (es) | Radioconjugados anti-psma y usos de estos | |
| MX2020010104A (es) | Conjugados de farmaco-anticuerpo anti-antigeno de membrana especifico de prostata (psma) humanizado. | |
| CO2023004252A2 (es) | Anticuerpos anti-ceacam5 y conjugados y usos de los mismos | |
| MX2021000783A (es) | Anticuerpos humanizados contra psma. | |
| CO2021009693A2 (es) | Proteínas de unión a antígeno del receptor gamma anti-il2 | |
| CL2023003607A1 (es) | Anticuerpos anti-ccr8 y usos de los mismos | |
| AR122270A1 (es) | Conjugados de anticuerpo-fármaco inhibidores de mcl-1 y sus métodos de uso | |
| BR112019000071A2 (pt) | conjugados adjuvantes de anticorpo | |
| MX2020002667A (es) | Proteinas de unión condicionalmente activadas restringidas. | |
| BR112019024632A2 (pt) | A proteína de ligação nkg2d, cd16 e um tumor-antigénio associado | |
| MX2022000325A (es) | Anticuerpos dirigidos contra dll3 y usos de los mismos. | |
| CO2020014343A2 (es) | Anticuerpos específicos para cd3 y sus usos | |
| ECSP23025680A (es) | Moléculas de unión a b7-h4 terapéuticas | |
| CO2023002375A2 (es) | Anticuerpos contra ilt2 y uso de los mismos | |
| CO2019003759A2 (es) | Anticuerpos que se unen a la proteína de envoltura del virus zika y usos de los mismos | |
| CY1124183T1 (el) | Συζευγματα αντισωματος εναντι-sez6 φαρμακου και μεθοδοi χρησης | |
| CO2022001021A2 (es) | Anticuerpos que se unen a células cancerosas yque dirigen radionucleidos a dichas células | |
| MX2024014591A (es) | Anticuerpo anti-bdca2 y uso del mismo | |
| AR120093A1 (es) | Anticuerpos anti-ceacam y usos de los mismos | |
| CO2023010353A2 (es) | Anticuerpos monoclonales anti-gprc5d y usos de los mismos | |
| CO2023000557A2 (es) | Anticuerpos y métodos para tratar enfermedades asociadas a claudina | |
| MX2021010254A (es) | Conjugados de anticuerpo-farmaco que comprenden anticuerpos anti-tm4sf1 y metodos de uso de los mismos. | |
| CL2025001502A1 (es) | Conjugados anticuerpo-fármaco anti-cea y métodos de uso | |
| CO2024001686A2 (es) | Anticuerpos anti-vegfr1 y sus usos |